Jade Biosciences, Inc. — Form 8-K
Filed July 1, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 52/100
What the filing says
On June 29, 2026, Jade Biosciences entered into an exclusive, worldwide, royalty-bearing license agreement with Paragon Therapeutics for monospecific antibodies targeting an undisclosed target across all therapeutic areas. Jade will pay up to $22.0M in development/regulatory milestones (including $1.5M paid in January 2026 and $2.5M due on first Phase 1 dosing) plus up to ~$20.1M in sublicensing fees, and royalties of low-to-mid single digits for monospecific products and mid-single digits for multispecific products based on net sales. Paragon committed not to conduct new campaigns targeting the same antigen for five years.
Why this rating
Moderate deal: ~$42.1M potential payments is ~14.5% of $289.4M market cap, material but contingent on success milestones. License provides asset pipeline access but target is undisclosed and development stage uncertain.
View original filing on SEC.gov ↗
See more from July 1, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.